• Experimental Drug Slows Decline In Alzheimer's Patients

    One year ago - By Active Beat

    Combined results from two studies show that Solanezumab, an Alzheimer's drug being developed by Eli Lilly & Co., might slow mental decline, particularly in milder Alzheimer's cases. The results were announced on Monday by researchers at a conference of the American Neurological Association in Boston.
    While the separate studies showed that the drug did not achieve the main goal of slowing the progress of Alzheimer's significantly, pooled results found that mild Alzheimer's patients administered with Solanezumab showed a 34 percent smaller decline compared to those given a placebo for 18...
    Read more ...

     

  • Innovative Treatment Could Slow Down Alzheimer's Disease

    One year ago - By Active Beat

    Solanezumab, a new drug created by Eli Lilly has shown promising results in two trails to clear plaques that are believed to be the cause of Alzheimer's. This is a major achievement for Eli Lilly as there only a few drugs that have been shown to make a difference in delaying this degenerative disease. The drugs currently approved for Alzheimer's treatments only help by eliminating symptoms not by treating the disease.
    In the two trials conducted solanezumab was effective in reducing the cognitive decline experienced by patients by 34%. The drug appears to work best on patients who at the...
    Read more ...